Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – October 13, 2021 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Wilcox

DUR Board Members:

Dr. Stephen Anderson –	participating in person
Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Markita Broyles –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://zoom.us/webinar/register/WN_4CSi96XAQPGwDxGIysVv4Q
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 932 1996 4037
Passcode: 31508686

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. September 8, 2021 DUR Board Meeting Minutes
   B. September 8, 2021 DUR Board Recommendations Memorandum

Items to be presented by Dr. Nawaz, Dr. Wilson, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Fall 2021 Pipeline Update – See Appendix B**
   A. Pharmacy Helpdesk Activity for September 2021
   B. Medication Coverage Activity for September 2021
   C. Fall 2021 Pipeline Update

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Herceptin® (Trastuzumab) and Margenza® (Margetuximab-cmkb) and Update the Approval Criteria for the Breast Cancer Medications – See Appendix C**
   A. Market News and Updates
   B. Margenza® (Margetuximab-cmkb) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Orgovyx™ (Relugolix) – See Appendix D**
   A. Market News and Updates
   B. Orgovyx™ (Relugolix) Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

7. **Action Item – Annual Review of Spinal Muscular Atrophy (SMA) Medications – See Appendix E**
   A. Current Prior Authorization Criteria
   B. Utilization of SMA Medications
   C. Prior Authorization of SMA Medications
   D. Market News and Updates
   E. College of Pharmacy Recommendations
   F. Utilization Details of SMA Medications

Items to be presented by Dr. Ford, Dr. Muchmore, Chairman:

8. **Action Item – Annual Review of Hepatitis C Mediations – See Appendix F**
   A. Introduction
   B. Current Prior Authorization Criteria
   C. Utilization of Hepatitis C Medications
   D. Prior Authorization of Hepatitis C Medications
   E. Market News and Updates
   F. College of Pharmacy Recommendations
   G. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

9. **Annual Review of Ovarian Cancer Medications – See Appendix G**
   A. Introduction
   B. Current Prior Authorization Criteria
   C. Utilization of Ovarian Cancer Medications
   D. Prior Authorization of Ovarian Cancer Medications
   E. College of Pharmacy Recommendations
   F. Utilization Details of Ovarian Cancer Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

10. **30-Day Notice to Prior Authorize Jakafi® (Ruxolitinib) and Rezurock™ (Belumosudil) – See Appendix H**
    A. Introduction
    B. Market News and Updates
    C. Jakafi® (Ruxolitinib) Product Summary
    D. Rezurock™ (Belumosudil) Product Summary
    E. College of Pharmacy Recommendations

Items to be presented by Dr. Ha, Dr. Muchmore, Chairman:

11. **Annual Review of Targeted Immunomodulator Agents and 30-Day Notice to Prior Authorize Lupkynis™ (Voclosporin) and Saphnelo™ (Anifrolumab-fnia) – See Appendix I**
    A. Current Prior Authorization Criteria
    B. Utilization of Targeted Immunomodulator Agents
    C. Prior Authorization of Targeted Immunomodulator Agents
    D. Market News and Updates
    E. Lupkynis™ (Voclosporin) Product Summary
    F. Saphnelo™ (Anifrolumab-fnia) Product Summary
    G. College of Pharmacy Recommendations
    H. Utilization Details of Targeted Immunomodulator Agents

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

12. **30-Day Notice to Prior Authorize Bylvay™ (Odevixibat) – See Appendix J**
    A. Introduction
    B. Bylvay™ (Odevixibat) Product Summary
    C. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

13. **Annual Review of Beta Thalassemia and Sickle Cell Disease (SCD) Medications – See Appendix K**
    A. Introduction
    B. Current Prior Authorization Criteria
    C. Utilization of Beta Thalassemia and SCD Medications
    D. Prior Authorization of Beta Thalassemia and SCD Medications
    E. Market News and Updates
    F. College of Pharmacy Recommendations
    G. Utilization Details of Beta Thalassemia and SCD Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. **U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix L**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

15. **Future Business* (Upcoming Product and Class Reviews)**
    A. Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications
    B. Atopic Dermatitis Medications
    C. Botulinum Toxins
    D. Multiple Myeloma Medications

    *Future product and class reviews subject to change.

16. **Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.